Thane: Bajaj Healthcare has announced that Dayashankar Patel, has tendered his resignation from the position of Chief Financial Officer (‘CFO’), Key Managerial Personnel (‘KMP’) of the Company due to personal reasons. He will be relieved from his duties after the closing of office hours of 15th April, 2025.In a regulatory filing with the BSE, the company acknowledged Patel’s contributions, stating, “The Company appreciates the valuable services tendered by him during his tenure.”Patel is a Chartered Accountant having experience of several years in finance and business planning, team management as well as financial control function. He has managed and supported business critical decisions like business case analysis, cost planning, financial modelling, revenue analysis and process review.Patel has done financial analysis and business development with expertise in leading multiple teams through project implementations.Read also: DCGI nod to Bajaj Healthcare for manufacturing Parkinson’s disease psychosis drug Pimavanserin in IndiaMeanwhile, Bajaj Healthcare continues to make strides in pharmaceutical advancements. As previously reported by Medical Dialogues, the company recently received a recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets in strengths of 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg.Read also: Bajaj Healthcare gets CDSCO panel nod for Phase III trials for anti-seizure drugBajaj Healthcare Limited is a Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993, it specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.Read also: Bajaj Healthcare gets rights to manufacture, distribute, sell Magnesium L Threonate in India